Abvc Biopharma (ABVC) Total Debt (2010 - 2026)

Abvc Biopharma (ABVC) has reported Total Debt for 15 consecutive years, with $118924.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Debt fell 93.18% year-over-year to $118924.0; the trailing twelve-month figure through Jun 2026 stood at $118924.0 (down 93.18% YoY), and the FY2025 full-year result was $1.5 million, down 10.09% from the prior year.
• Total Debt fell to $118924.0 in Q2 2026 per ABVC's latest filing, from $177474.0 in the prior quarter.
• Across five years, Total Debt topped out at $3.8 million in Q4 2022 and bottomed at $118924.0 in Q2 2026.
• Historically, Total Debt has averaged $1.6 million across 5 years, with a median of $1.7 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Total Debt soared 104.35% in 2024, then tumbled 93.18% in 2026.
• Over 5 years, Total Debt stood at $3.8 million in 2022, then plunged by 52.51% to $1.8 million in 2023, then declined by 6.56% to $1.7 million in 2024, then decreased by 10.09% to $1.5 million in 2025, then slumped by 92.13% to $118924.0 in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $118924.0, $177474.0, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.